The ATM/ATR-CHK1/2 signaling cascades activated by MEDI2228 treatment increase NKG2D ligands in MM cells and primes MM cells to natural killer (NK) cell-mediated cytotoxicity by increasing expression of MICA/B in MM cells to enhance binding and activating NK cytolytic activity. The gene discussed is KLRK1; the disease is Miyoshi myopathy.